Reinhard von Roemeling
Chief Tech/Sci/R&D Officer at CURIS, INC.
Reinhard von Roemeling active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CURIS, INC. | Chief Tech/Sci/R&D Officer | 13/08/2019 | - |
Career history of Reinhard von Roemeling
Former positions of Reinhard von Roemeling
| Companies | Position | Start | End |
|---|---|---|---|
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - | - |
Training of Reinhard von Roemeling
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Statistics
International
| United States | 3 |
| Germany | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
